Literature DB >> 7224255

Reversal of tricyclic-antidepressant-induced cardiac conduction abnormalities by phenytoin.

G A Hagerman, P K Hanashiro.   

Abstract

Ten patients with cardiac conduction defects due to severe tricyclic antidepressant poisoning were successfully treated with intravenous phenytoin. Eight patients had combined first degree AV block and intraventricular conduction delay; one patient had first degree AV block alone; and one patient had intraventricular conduction delay alone. Phenytoin was injected at a rate of 50 mg/min in amounts not exceeding 500 mg (approximately 5 mg/kg to 7 mg/kg). Five patients had complete normalization within 46 min. The remaining five patients showed improvement in their conduction defects shortly after phenytoin treatment, with complete normalization occurring within 14 hr. This investigation demonstrated the effectiveness of phenytoin in reversing tricyclic-antidepressant-induced cardiac conduction abnormalities. Phenytoin is a logical drug for the treatment of severe tricyclic antidepressant poisoning signalled by first degree AV block and/or intraventricular conduction delay.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7224255     DOI: 10.1016/s0196-0644(81)80342-3

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

Review 1.  Tricyclic antidepressant overdose: a review.

Authors:  G W Kerr; A C McGuffie; S Wilkie
Journal:  Emerg Med J       Date:  2001-07       Impact factor: 2.740

2.  Alkalinization therapy for tricyclic antidepressant overdose.

Authors:  M Callaham
Journal:  West J Med       Date:  1981-05

3.  Tricyclic antidepressant poisoning. Management of arrhythmias.

Authors:  P R Pentel; N L Benowitz
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 4.  Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup.

Authors:  Christopher Yates; Tais Galvao; Kevin M Sowinski; Karine Mardini; Tudor Botnaru; Sophie Gosselin; Robert S Hoffman; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Semin Dial       Date:  2014-04-09       Impact factor: 3.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.